Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
about
Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitroClinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapyProfile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDSTherapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical TrialsCritical appraisal of elvitegravir in the treatment of HIV-1/AIDS.Single-Tablet Regimens in HIV TherapyS/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges.Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neuronsPharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaquesReduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutationsReal-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.The protease inhibitors and HIV-associated bone loss.Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infectionElvitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate tablets.Pharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment.Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV.Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients.Role of raltegravir in HIV-1 management.Pharmacology of HIV integrase inhibitors.Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.Safety of pharmacoenhancers for HIV therapy.Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.Cobicistat: a new boost for the treatment of human immunodeficiency virus infection.Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.Cobicistat : a new opportunity in the treatment of HIV disease?Pharmacokinetic enhancers in HIV therapeutics.The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV.Darunavir/cobicistat once daily for the treatment of HIV.Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.Elvitegravir for the treatment of HIV.Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir.Treating HIV-1 Infection: What Might the Future Hold?Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran.Atazanavir sulfate + cobicistat for the treatment of HIV infection.Elvitegravir concentrations in seminal plasma in HIV-1-infected men.Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients.Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
P2860
Q24633870-F0A91617-13FB-4CAE-9BD3-85B4A24BA6DAQ26771182-E7BEEC97-243E-4281-98F3-1B9823F9B01DQ28073206-FCB58D2D-99BA-471F-AFFA-D67C9AF4FE97Q28553571-D905B1B5-683E-43B1-9841-C5C0DA9A22CAQ33680234-B28CE12A-F0BD-457A-A692-D7E6BF4F9B1DQ33939110-52B3E474-2F66-4142-91E2-8AC50EEC0559Q34168983-6B3EE5B5-4C03-4D69-8969-17C22B4F6FD6Q34634156-C05F3470-A83E-4D30-878E-79A920594D08Q35145361-8DD623FF-7711-4338-A75D-A2D5A5A12F85Q35432739-7346B672-DD0E-4875-9CD0-0D0EE6CB5E0CQ35607763-1D845ECB-97A5-4A4B-A34A-6365DFFB0752Q36219963-18B80C30-BAA9-42EC-A682-815932ED3549Q36818259-7C50A530-7686-4B8F-8226-E0EF72DA6BAAQ37014157-AA5B02C2-B11A-4315-B04A-3A765DC95F62Q37339933-089CE336-58E0-4FC6-8A99-A0830018805FQ37713076-1ACAE6BB-1E35-41C3-87CF-35FDDC022134Q37818237-F6E107E4-75F5-4855-ACB8-3570CE6CD886Q37845854-AA3E2CF6-C5F4-44B4-A70D-920489F50A14Q38002011-625A01FB-C927-422F-9684-34CB3F2B1883Q38025835-DFC45923-5A09-4A92-BA6F-DB1DDC5FFBF9Q38030981-3F479F4F-53B8-4F80-B6FB-6A4527EE2F9EQ38057371-28819153-5F03-49C6-9DA0-E071AC3A20D6Q38058501-472504DD-B3A0-4FE0-A30E-81876C90D4F5Q38087555-E4131469-A616-45DF-ACD0-FD41B94764FFQ38171345-AAD43767-FC10-40F0-87D4-2B2E7DA17F1FQ38211165-443F5101-6657-4182-856B-2F17B523F539Q38244014-F40AD8EE-68EA-4B48-AC56-C75DB93CC714Q38305617-8EEA52D9-CF15-4B04-A964-CF025D18B98DQ38472696-BDB3D85E-343F-4377-8251-09E6FA1B54B3Q38719799-46AEAFF1-C1A6-42DF-8E67-5CC6DD64E320Q38868949-CF019173-A3AF-4F44-848F-B2FA378D3FCAQ38987327-B9AB5499-04A2-4C8D-B642-946AA7CF1EF9Q39118603-70764E75-1369-4CE8-96F4-E720722773E6Q39712911-B2FCC3EE-0171-45BB-A511-B1971B1C2BE3Q40077147-F3250F7E-1C6C-4339-9F44-62E259AD7849Q40237526-A4E02CDF-913D-476A-8637-6420295C291DQ40593858-CD7E8B1B-FC20-4DD4-8542-772DDB849401Q40766725-0F6AAE70-9660-4FD4-B977-B687873A1F4AQ41141601-3851508B-79DA-4745-A702-E2BF68EFC34BQ41686477-C72204DC-9C44-4EDC-BD22-CB42C6A249C9
P2860
Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Pharmacokinetics and bioavaila ...... imen for the treatment of HIV.
@en
Pharmacokinetics and bioavaila ...... imen for the treatment of HIV.
@nl
type
label
Pharmacokinetics and bioavaila ...... imen for the treatment of HIV.
@en
Pharmacokinetics and bioavaila ...... imen for the treatment of HIV.
@nl
prefLabel
Pharmacokinetics and bioavaila ...... imen for the treatment of HIV.
@en
Pharmacokinetics and bioavaila ...... imen for the treatment of HIV.
@nl
P2093
P1476
Pharmacokinetics and bioavaila ...... imen for the treatment of HIV.
@en
P2093
Brian P Kearney
David Warren
Polina German
Steve West
P304
P356
10.1097/QAI.0B013E3181EB376B
P407
P577
2010-11-01T00:00:00Z